Market Cap
$3.4B
CDNA
CareDx, Inc.
$67.15 ▲ +1.39%
Prev close $66.23Market cap$3.4B
ConsensusBuy
12-mo target$58.83 (-12.4%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (6 insiders)High Impact Filing (8/10)19 New Institutional Positions9 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on CDNA right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Buy (69%)
Inst. Holders
50 funds
Inst. Value
$1.0B
Inst. Activity
19 buys / 9 sells
Insider Activity
$0.00 buy / $12.3M sell
Insider Net $
-$12.3M
Social Sentiment
50° Neutral
SEC Reports
9
Price chart 30d +34.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: CDNA — 68.8% short (0.6M / 0.9M)
Short: 624,946 | Exempt: 651 | TRF Vol: 908,854 | Short Ratio: 68.8% | Off-exchange volume (dark poo
Sep 12, 2026 Insider
Kennedy Keith surrendered for taxes 8,220 shares
CFO & COO @ $52.37 ($430.5K)
Sep 12, 2026 Insider
Aug 7, 2026 SEC Meng Jessica surrendered for taxes 6,688 shares
Chief Commercial Officer @ $52.37 ($350.3K)
CareDx directors Cournoyer, Bickerstaff, and Goldberg made open-market sales totaling $3.78M from Aug 4-5 at ~$46-47/sha
CLUSTER — Impact 3/10
Aug 5, 2026 Insider
Aug 4, 2026 SEC Novack Jeffrey Adam sold 2,188 shares
Secretary and General Counsel @ $46.15 ($101.0K)
Director Christine Cournoyer filed a Form 144 notice to sell 16,000 common shares of CareDx with an estimated market val
144 — Impact 2/10
CareDx (CDNA) CEO John Hanna and Director Hannah Valantine sold a combined ~$5.5M in open-market shares on July 16, 2026
CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
BAMCO INC /NY/ — TRIM
1,937,326 shares ($55.2M)
Analyst ratings buy % +3.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
69% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 24, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Sep 2, 2026 | Canaccord Genuity | INITIATE | Buy | 47% |
| Aug 6, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Jul 31, 2026 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Jul 16, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Apr 29, 2026 | BTIG | MAINTAIN | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 4 | 4 | 0 | 0 | 69% | |
| Aug 1, 2026 | 5 | 3 | 5 | 0 | 0 | 62% | |
| Jul 1, 2026 | 5 | 3 | 5 | 0 | 0 | 62% | |
| Jun 1, 2026 | 5 | 3 | 5 | 0 | 0 | 62% | |
| May 1, 2026 | 5 | 4 | 5 | 0 | 0 | 64% | |
| Apr 1, 2026 | 5 | 4 | 6 | 0 | 0 | 60% | |
| Mar 1, 2026 | 5 | 4 | 6 | 0 | 0 | 60% | |
| Feb 1, 2026 | 4 | 4 | 6 | 0 | 0 | 57% |
Price targets
Where 6 covering analysts think CDNA trades over the next 12 months.
$58.83 -12.4% upside Sell
Current$67.15 Low$46.00 Median$61.00 High$74.00 6 analysts
$46.00$74.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 4.6/10.
NEUTRALCLUSTER3/10
CareDx directors Cournoyer, Bickerstaff, and Goldberg made open-market sales totaling $3.78M from Au
Aug 7, 2026
NEUTRAL1442/10
Director Christine Cournoyer filed a Form 144 notice to sell 16,000 common shares of CareDx with an
Aug 4, 2026
NEUTRALCLUSTER4/10
CareDx (CDNA) CEO John Hanna and Director Hannah Valantine sold a combined ~$5.5M in open-market sha
Jul 18, 2026
NEUTRALCLUSTER2/10
Two CareDx insiders (CEO and a director) sold a combined $808K in open-market sales over a 5-day win
Jun 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: CDNA — 68.8% short (0.6M / 0.9M)
Short: 624,946 | Exempt: 651 | TRF Vol: 908,854 | Short Ratio: 68.8% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: CDNA — 59.5% short (0.7M / 1.2M)
Short: 705,452 | Exempt: 1,038 | TRF Vol: 1,185,014 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: CDNA — 57.4% short (0.7M / 1.2M)
Short: 690,365 | Exempt: 3,950 | TRF Vol: 1,203,005 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: CDNA — 56.7% short (0.4M / 0.6M)
Short: 353,539 | Exempt: 180 | TRF Vol: 624,008 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: CDNA — 58.9% short (0.4M / 0.6M)
Short: 360,133 | Exempt: 4,075 | TRF Vol: 611,733 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.26 | $0.24–$0.27 | -8.9% | +2.0% | 5↑ 0↓ | $0.1B | 6 |
| Next Q | $0.23 | $0.17–$0.27 | 93.1% | -8.6% | 5↑ 0↓ | $0.1B | 6 |
| Current FY | $1.20 | $1.15–$1.23 | 106.6% | -1.2% | 5↑ 0↓ | $0.5B | 6 |
| Next FY | $1.29 | $1.17–$1.47 | 7.6% | -4.8% | 4↑ 1↓ | $0.5B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.255 | — |
| 7d ago | $0.251 | +0.004 |
| 30d ago | $0.250 | +0.005 |
| 60d ago | $0.230 | +0.025 |
| 90d ago | $0.188 | +0.067 |
Institutional ownership
Which big funds own CDNA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.0B total value (36,242,574 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 19 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 4,814,709 | $137.2M | 13.3% | — |
| STATE STREET CORP | 2,468,858 | $70.4M | 6.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,197,475 | $62.6M | 6.1% | — |
| ARK Investment Management LLC | 1,953,531 | $55.7M | 5.4% | — |
| Boston Partners | 1,937,601 | $55.2M | 5.3% | DOUBLED +108.8% |
| BAMCO INC /NY/ | 1,937,326 | $55.2M | 5.3% | TRIM -41.9% |
| Chevy Chase Trust Holdings, LLC | 1,437,416 | $41.0M | 4.0% | ADD +39.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,328,037 | $37.9M | 3.7% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,242,959 | $35.4M | 3.4% | — |
| Sumitomo Mitsui Trust Group, Inc. | 1,191,630 | $34.0M | 3.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BAMCO INC /NY/ | TRIM | 3,336,409 | 1,937,326 | -41.9% | $55.2M |
| D. E. Shaw & Co., Inc. | ADD | 874,908 | 1,137,660 | +30.0% | $32.4M |
| MORGAN STANLEY | ADD | 425,349 | 774,299 | +82.0% | $22.1M |
| JANE STREET GROUP, LLC | ADD | 250,351 | 470,273 | +87.8% | $13.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | — | 372,111 | — | $10.6M |
| Qube Research & Technologies Ltd | NEW | — | 369,837 | — | $10.5M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 370,183 | 268,207 | -27.5% | $7.6M |
| Aberdeen Group plc | TRIM | 417,744 | 224,829 | -46.2% | $6.4M |
| HSBC HOLDINGS PLC | DOUBLED | 38,387 | 196,250 | +411.2% | $5.6M |
| Nuveen, LLC | TRIM | 390,294 | 152,509 | -60.9% | $4.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$12.3M — $0.00 bought, $12.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 12, 2026 | Kennedy Keith | CFO & COO | TAX W/H | 8,220 | $52.37 | $430.5K |
| Sep 12, 2026 | Meng Jessica | Chief Commercial Officer | TAX W/H | 6,688 | $52.37 | $350.3K |
| Aug 5, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | SELL | 2,188 | $46.15 | $101.0K |
| Aug 5, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | SELL | 500 | $46.75 | $23.4K |
| Aug 5, 2026 | Bickerstaff George | Director | SELL | 20,000 | $46.29 | $925.7K |
| Aug 4, 2026 | COURNOYER CHRISTINE | Director | SELL | 16,000 | $46.94 | $751.0K |
| Aug 4, 2026 | Goldberg Michael | Director | SELL | 44,700 | $47.06 | $2.1M |
| Aug 1, 2026 | Novack Jeffrey Adam | Secretary and General Counsel | TAX W/H | 2,872 | $47.85 | $137.4K |
| Jul 16, 2026 | Valantine Hannah | Director | EXERCISE | 7,606 | $20.56 | $156.4K |
| Jul 16, 2026 | Valantine Hannah | Director | EXERCISE | 16,048 | $14.19 | $227.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CDNA.
Shares short
6,297,191
Settlement Sep 15, 2026
Change vs prior
+8.0%
Semi-monthly cycle
Days to cover
6.3
At avg daily volume
Of shares outstanding
≈12.2%
Estimate — not % of float
All CDNA filing & press-release reports (9)
- CLUSTER reportAug 7, 2026
- 144 reportAug 4, 2026
- CLUSTER reportJul 18, 2026
- CLUSTER reportJun 16, 2026
- DEFA14A reportJun 5, 2026
- S-3ASR reportApr 28, 2026
- 8-K reportApr 16, 2026
- 8-K/A reportFeb 26, 2026
- 8-K reportFeb 24, 2026